Cancer cells have a distinct chemical signature, a molecular fingerprint.
In laboratories across the English Midlands, researchers have found a way to listen to the chemical language of cancer itself — reading the molecular fingerprint of tumor cells as they drift through a patient's blood. A technique long used in materials science has been turned toward one of medicine's most urgent problems: catching lung cancer early enough to matter. If the larger trials ahead confirm what early results suggest, the months-long ordeal of cancer diagnosis may one day begin with nothing more than a blood draw.
- Lung cancer's deadliest advantage has always been time — most cases are caught late, when treatment options narrow and outcomes worsen.
- Circulating tumor cells, the very cells that carry cancer from one part of the body to another, have been nearly impossible to reliably detect until now.
- A team from three UK institutions has demonstrated they can identify a single cancer cell in a blood sample using infrared light and a computer — with equipment already sitting in most hospital pathology labs.
- The method sidesteps the cost and complexity of existing detection approaches, dramatically lowering the barrier for hospitals to adopt it.
- Larger patient trials are now being planned, with researchers eyeing applications beyond lung cancer — suggesting this could become a broad platform for real-time cancer monitoring.
British researchers have developed a blood test capable of detecting lung cancer cells as they circulate through the body — a potential turning point in how quickly and gently the disease can be identified. The technique, Fourier Transform Infrared microspectroscopy, works by directing an intense infrared beam at a blood sample on a standard glass slide. Cancer cells absorb that light in a chemically distinct way, and a computer reads that pattern to determine whether tumor cells are present. The team has already shown it can detect a single lung cancer cell in a patient's blood.
The institutions behind the work — University Hospitals of North Midlands NHS Trust, Keele University, and Loughborough University — have targeted a specific and consequential problem. Circulating tumor cells are not merely evidence of cancer; they are the mechanism by which it spreads to distant organs. Catching them early is both a diagnostic opportunity and a chance to intervene before a localized disease becomes a systemic one.
What makes the approach especially promising is its practicality. Existing methods for finding these cells are expensive, slow, and often unreliable, partly because the cells alter their characteristics as they move through the bloodstream. The new technique uses equipment already found in pathology labs, requiring no major new investment from hospitals. Published in Applied Spectroscopy, the research makes a credible case for moving from the laboratory into clinical routine.
Lead author Professor Josep Sulé-Suso emphasized that earlier detection means earlier treatment — and the possibility of monitoring how a patient's cancer responds to therapy in real time, reducing the need for invasive procedures. The team is now planning larger trials aimed at producing a rapid, automated test that could be integrated into standard cancer care, with ambitions to extend the method to other cancer types entirely.
British researchers have engineered a blood test that can spot lung cancer cells as they circulate through the body, a breakthrough that could compress the months-long diagnostic journey into something far faster and less invasive. The technique, called Fourier Transform Infrared microspectroscopy, works by aiming a powerful infrared beam—similar in principle to the light in a television remote, but vastly more intense—at a blood sample on a standard glass slide. Cancer cells have a distinct chemical signature, a kind of molecular fingerprint that absorbs infrared light in a particular way. A computer analyzes that absorption pattern and identifies whether circulating tumor cells are present.
The research team, drawn from University Hospitals of North Midlands NHS Trust, Keele University, and Loughborough University, has already demonstrated the method's sensitivity by detecting a single lung cancer cell in a patient's blood. This matters because circulating tumor cells—cells that break free from a primary tumor and travel through the bloodstream—are both a window into how disease is advancing and a mechanism by which cancer spreads to distant organs. They are, in other words, the cells that turn a localized problem into a systemic one.
Until now, finding these cells has been a laborious affair. Existing detection methods are complicated, expensive, and time-consuming. They often fail to catch cancer cells at all, partly because the cells change their characteristics while moving through the blood, making them harder to recognize. The new approach sidesteps many of these obstacles. It uses equipment already present in pathology laboratories—standard glass slides and an infrared instrument—which means hospitals would not need to invest in entirely new infrastructure to adopt it. The simplicity and affordability of the method, published in the journal Applied Spectroscopy, make it far more likely to move from research into everyday clinical use.
Professor Josep Sulé-Suso, the lead author and an associate specialist in oncology at UHNM, framed the implications broadly. Earlier diagnosis means patients can begin treatment sooner, when interventions are often most effective. Personalized treatment becomes possible when doctors can monitor how a patient's cancer cells respond to therapy in real time, adjusting course as needed. And fewer invasive procedures—biopsies, imaging studies, exploratory surgeries—means less physical burden on patients already dealing with a serious illness.
The researchers are now planning larger trials to refine the method and move toward a rapid, automated blood test that could be woven into standard cancer care pathways. They also see potential for the technique to extend beyond lung cancer to other malignancies. What began as a laboratory innovation—a way to read the chemical language of cancer cells—could eventually reshape how oncologists detect, monitor, and treat disease across multiple cancer types.
Citas Notables
This approach has the potential to help patients receive earlier diagnoses, personalised treatments, and fewer invasive procedures, and it could eventually be applied to many types of cancer beyond lung cancer.— Professor Josep Sulé-Suso, lead author and Associate Specialist in Oncology at UHNM
La Conversación del Hearth Otra perspectiva de la historia
Why does detecting a single cell matter? Doesn't cancer involve millions of cells?
One circulating tumor cell is a signal. It means cancer has already begun to spread, or is about to. Finding it early, before a patient has symptoms or before imaging shows a tumor, changes everything about treatment options.
So this is really about speed—getting answers faster than a biopsy or CT scan?
Speed, yes, but also gentleness. A blood draw is routine. A biopsy is surgery. If you can answer the question with a needle and a vial, you've spared someone pain and recovery time.
The infrared beam—is that dangerous? Are there side effects?
No. It's just light, and the sample sits on a slide. There's no radiation exposure, no injection of dye. The beam reads the cell's chemistry and moves on.
What's the catch? Why isn't this already in hospitals?
It's new. It works in the lab, but it hasn't been tested on hundreds of patients yet. Hospitals need to know it's reliable before they change how they work. That's what the larger trials will show.
If it works, how long before a patient could get this test?
That depends on the trials. If the next phase goes well, maybe three to five years before it becomes standard. But some hospitals might start using it sooner, especially if they're research centers.